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Background. A promising clinical application for stem and progenitor cell transplantation is in rescue therapy for
degenerative diseases. This strategy seeks to preserve rather than restore host tissue function by taking advantage of unique
properties often displayed by these versatile cells. In studies using different neurodegenerative disease models, transplanted
human neural progenitor cells (hNPC) protected dying host neurons within both the brain and spinal cord. Based on these
reports, we explored the potential of hNPC transplantation to rescue visual function in an animal model of retinal
degeneration, the Royal College of Surgeons rat. Methodology/Principal Findings. Animals received unilateral subretinal
injections of hNPC or medium alone at an age preceding major photoreceptor loss. Principal outcomes were quantified using
electroretinography, visual acuity measurements and luminance threshold recordings from the superior colliculus. At 90–
100 days postnatal, a time point when untreated rats exhibit little or no retinal or visual function, hNPC-treated eyes retained
substantial retinal electrical activity and visual field with near-normal visual acuity. Functional efficacy was further enhanced
when hNPC were genetically engineered to secrete glial cell line-derived neurotrophic factor. Histological examination at
150 days postnatal showed hNPC had formed a nearly continuous pigmented layer between the neural retina and retinal
pigment epithelium, as well as distributed within the inner retina. A concomitant preservation of host cone photoreceptors
was also observed. Conclusions/Significance. Wild type and genetically modified human neural progenitor cells survive for
prolonged periods, migrate extensively, secrete growth factors and rescue visual functions following subretinal trans-
plantation in the Royal College of Surgeons rat. These results underscore the potential therapeutic utility of hNPC in the
treatment of retinal degenerative diseases and suggest potential mechanisms underlying their effect in vivo.
Citation: Gamm DM, Wang S, Lu B, Girman S, Holmes T, et al (2007) Protection of Visual Functions by Human Neural Progenitors in a Rat Model of
Retinal Disease. PLoS ONE 2(3): e338. doi:10.1371/journal.pone.0000338
INTRODUCTION
Retinal degenerative diseases that target photoreceptors or the
adjacent retinal pigment epithelium (RPE) affect millions of people
worldwide. Similar to many other neurodegenerative diseases, no
effective treatments are available for patients afflicted with these
blinding disorders. With advances in stem and progenitor cell
technology,however, novel cell-based therapies are being envisioned
[1–4].
In the CNS, transplanted human neural progenitor cells derived
from prenatal cortex (hNPC
ctx) display characteristics important for
cell-based rescue of degenerating neurons. They are highly
expandable in culture [5], demonstrate a capacity to survive,
migrate and integrate into damaged neural tissue [6–9], and can
delay cell death and/or functional loss in multiple animal models of
neurodegenerative disease [10–12]. Furthermore, they can express
transgenes encoding specific neurotrophic factors that have pro-
tective effects on neighboring host neurons [11,12]. Despite their
promise, the utility of hNPC
ctx to rescue vision following subretinal
transplantation in models of retinal degenerative disease has not
beenexaminedtoourknowledge.Sucha treatmentapproachmight
reduce the need for tailored gene replacement strategies for the
genetically heterogenous group of disorders collectively referred to
as retinitis pigmentosa. It may also be applicable in genetically
complex or multifactorial retinal degenerative diseases such as age-
related macular degeneration and glaucoma.
In the past, neural stem and progenitor cells from various
sources were introduced into eyes with the thought that they might
differentiate and replace photoreceptors lost in retinal disease [13–
19]. Reports showed that while neural progenitors migrated into
the retina and assumed the morphology of neurons, they failed to
express retina-specific markers, including those characteristic of
photoreceptors. However, their impact on host retinal function
was not tested. The aim of the present study was to determine
whether unmodified hNPC
ctx could rescue visual functions and if
engineered expression of a neurotrophic factor could enhance such
effects. Glial cell line-derived neurotrophic factor (GDNF) was
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sprouting, prevents cell death [20,21] and has neuroprotective
effects in the brain [11,22–24], spinal cord [12] and retina [25–
30], and because receptors for GDNF are expressed within mature
retina [26,31–34].
We transplanted unmodified and GDNF-expressing hNPC
ctx
(hNPC
ctx-GDNF) to the subretinal space of the Royal College of
Surgeons (RCS) rat. In this well-studied model of autosomal
recessive retinitis pigmentosa and secondary photoreceptor de-
generation, a MERTK mutation in the RPE compromises their
ability to phagocytose shed photoreceptor outer segments [35–37].
This defect produces a debris zone between photoreceptors and
RPE, with subsequent loss of the photoreceptors themselves. We
found that unmodified hNPC
ctx possess a striking ability to
preserve retinal activity and sustain a wide range of visual
functions. Some, but not all, of these effects were augmented in the
presence of GDNF-expressing cells. This report is significant for
the unique disposition of the transplanted hNPC
ctx and for the
subsequent levels of functional rescue achieved, which are among
the best encountered in the RCS rat [29,38–43].
METHODS
Cell culture
Human NPC
ctx were isolated from post mortem fetal cortical
brain tissue at 13.5 weeks gestation and designated as cell culture
M031. The method of collection conformed to the NIH guidelines
for the collection of such tissues, as well as the IRB requirements
for the University of Wisconsin. Human NPC
ctx were cultured as
spherical aggregates (neurospheres) in DMEM/HAMS F12 (3:1)
supplemented with B27 (1:50; Gibco, Carlsbad, CA), 20 ng/ml
EGF (Sigma-Aldrich, St. Louis, MO), 20 ng/ml FGF-2 (R&D
Systems, Minneapolis, MN) and 5 mg/ml heparin (Sigma).
Neurospheres were passaged by chopping as described previously
[5] and half the medium was exchanged every four days. After
four weeks in culture, the FGF-2, heparin and B27 were removed
and N2 (1:100; Invitrogen) was added. After ten weeks in culture,
10 ng/ml leukemia inhibitory factor (Chemicon, Temecula, CA)
was also added.
Lentiviral infection
A self-inactivating lentiviral construct containing a mouse phos-
phoglycerate kinase-1 internal promoter driving the human gene
encoding GDNF [44] was used to generate GDNF-secreting
hNPC
ctx. Prior to infection, high-titer lentiviral stocks were
obtained by ultracentrifugation and the particle content of
individual batches was determined by p24 antigen ELISA and
RT-qPCR quantification of viral RNA [45]. Human NPC
ctx
neurospheres were incubated with Accutase (Chemicon; one ml
per estimate of 10 million cells) for 10 minutes, followed by a five
minute incubation with an equal volume of 0.2% trypsin inhibitor.
After removal of the trypsin inhibitor, the spheres were washed
three times with 10 ml of medium. Cells were dissociated by
trituration, counted on a hemocytometer and resuspended in
conditioned medium at 1000 cells/ml. 300,000 cells were plated
per well of a 24-well plate (minimum 10 wells) and mixed with
virus (80 ng p24/10
6 cells) diluted in 100 ml of fresh medium. Cells
re-associated in the presence of virus and formed spheres within
three days, whereupon they were collected and seeded in flasks at
a density of approximately 500,000 cells/ml. After one month,
expanded cultures of transgenic (hNPC
ctx-GDNF) and unmodified
(hNPC
ctx) neurospheres from the same original culture were
cryoprotected and banked in liquid nitrogen for later use. For the
transplantation experiments performed in this study, hNPC
ctx-
GDNF and hNPC
ctx neurosphere cultures were thawed and
further expanded to passage 24 (equivalent to approximately 39
population doublings), a point at which they exhibit steady-state
growth and cell fate potential in vitro [46].
Preparation of cells for transplantation
One hour beforesurgery,hNPC
ctx-GDNF or hNPC
ctx neurospheres
were dissociated for 10 minutes in Accutase (1 ml/10 million cells)
followed by inactivation with an equal volume of 0.2% trypsin
inhibitor. Neurospheres were washed twice with 10 ml of medium,
gently triturated,and counted on a hemocytometer. Cellsuspensions
were diluted to a final concentration of 10
4 cells/ml in DMEM/F12
(3:1) andkepton iceuntiltransplantation.Trypanbluedyeexclusion
was performed on cell suspensions prior to and immediately
following each transplantation session, which showed greater than
90% and 75% cell survival, respectively.
Growth factor ELISAs and GDNF
immunocytochemistry
Neurospheres containing either hNPC
ctx or hNPC
ctx-GDNF were
dissociated with Accutase, washed and resuspended in plating
medium (DMEM/F12 (3:1) with 2% B27) at a density of 1000
cells/ml. Cells were plated either on glass coverslips (40,000 cells/
coverslip) coated with poly-L lysine and laminin or six-well plates
(10
6 cells/well) coated with laminin alone. Cells were then
maintained for three weeks by exchanging half the media with
fresh plating media every three to four days. After three weeks, all
medium from the six-well cultures was removed, followed by
a single media wash and replacement with fresh medium for
24 hours. Conditioned medium was collected and protein levels of
GDNF, IGF-1, and FGF-2 were quantified by ELISA (R&D
Systems) according to the manufacturer’s protocols. The plated
cells were then dissociated and counted using a hemocytometer in
order to express results as picograms or nanograms of growth
factor produced per day per million cells. Coverslips plated with
acutely dissociated hNPC
ctx-GDNF or hNPC
ctx were fixed with
4% paraformaldehyde, washed with PBS, blocked in 5% normal
donkey serum and 0.1% Triton X-100, and incubated with goat
anti-GDNF (1:100; R&D Systems) primary antibody followed by
donkey anti-goat Cy3-conjugated secondary antibody (1:1000;
Jackson IR). Nuclei were counterstained with Hoechst 33258
(1:10,000; Sigma) and coverslips were mounted in GelTol
Aqueous mounting media (Immunotech). At least five fields from
each of three coverslips were photographed with a Nikon E600
equipped with epifluorescence, using SPOTcam and SPOT
advanced software (Diagnostic Instruments, Inc.). Fluorescence
was quantified using Metamorph software and data was expressed
as mean6SEM.
Animals
Twenty-one day old pigmented dystrophic RCS rats (rdy
+,p
+)
received unilateral subretinal injections of hNPC
ctx (2610
4/2 ml/
eye) (n=21), hNPC
ctx-GDNF (n=11), or carrier medium only
(n=4) (sham surgery). Further sham-operated RCS rats from
separate, concurrent studies [42,43] were available for comparison
and yielded similar results (these animals were not included in the
present study). For each animal included in this study, fellow eyes
served as untreated, internal controls. All animals were maintained
on cyclosporine A (Novartis), administered in the drinking water
(210 mg/l; resulting blood concentration of around 300 mg/liter
[40]), from one day prior to transplantation until they were
sacrificed. All animals also received daily dexamethasone injec-
tions (1.6 mg/kg, i.p.) for 2 weeks, starting from the day of
Vision and Neural Progenitors
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under the supervision of the Institutional Animal Care Committee
at the University of Utah; all animals were treated in accordance
with the Policies on the Use of Animals and Humans in
Neuroscience Research, approved by the Society for Neuroscience
in January 1995.
Transplantation
In order to study rescue effects following surgery, donor cells were
introduced at P21, an age preceding major onset of photoreceptor
loss. Separate transplantation sessions were performed using
different batches of cells in order to ensure that results were
repeatable. Suspensions of hNPC
ctx or hNPC
ctx-GDNF containing
about 2610
4 cells were delivered into the subretinal space of one
eye through a small scleral incision as a suspension in 2 mlo f
DMEM/F12 medium (Invitrogen) using a fine glass pipette
(internal diameter 75–150 mm) attached by tubing to a 10 ml
Hamilton syringe. The cornea was punctured to reduce in-
traocular pressure and limit the efflux of cells. A sham-operated
group was treated in an identical manner, except carrier medium
alone was injected. Immediately after injection, the fundus was
examined for retinal damage or signs of vascular distress. Any
animal showing such problems was removed from the study and
not included in the final animal counts.
Electroretinogram (ERG)
Dark adapted full field ERG responses were recorded at
approximately P100 as in previous studies [38]. Cone responses
were isolated by employing a double flash protocol in which
a conditioning flash was followed by a probe flash one second
later. The conditioning flash served to transiently saturate rods so
that they were rendered unresponsive to the probe flash. The
intensity of the conditioning flash for complete rod bleaching was
set to 1.4 log cds/m
2 for all tests. A composite b-wave was
obtained by presenting the probe flash alone, i.e., without being
preceded by a conditioning flash. The response to the probe flash
(1.4 log cds/m
2), preceded by the conditioning flash, was taken as
reflecting cone-driven activity, and allowed the rod contribution to
be derived by subtraction of the cone response from the composite
response. Special care was taken to maintain the electrode
placement in a consistent position in all animals. Averages of 3–
5 traces (set 2 minutes apart to ensure recovery of rod
responsiveness) were obtained.
Visual acuity records obtained by measuring
optomotor responses
Animals were tested for spatial visual acuity at approximately P100
using an Optomotry testing apparatus [47]. This device consists of
a rotating cylinder covered with a vertical sine wave grating
presented invirtualthree-dimensional (3-D)space onfour computer
monitors arranged in a square. Unrestrained rats were placed on
a platform in the center of the square, where they tracked the
grating with reflexive head movements. The spatialfrequency of the
grating was clamped at the viewing position by repeatedly re-
centering the ‘cylinder’ on the head of the test subject. Acuity was
quantified by increasing the spatial frequency of the grating using
a psychophysics staircaseprogression untiltheoptokineticreflexwas
lost, thereby obtaining a maximum threshold.
Luminance threshold responses
To measure luminance threshold, single and multiunit activity was
recorded in the superior colliculus (SC) at approximately P100
using a modification of a previously described procedure [48].
Recordings were made from the superficial layers of the SC to
a depth of 100–300 mm using glass-coated tungsten electrodes
(resistance: 0.5 MV; bandpass 500 Hz–5 KHz). Brightness of a 5u
spot was varied with neutral density filters (minimum steps of 0.1
log) until a response was obtained that was double the background
activity, yielding the threshold level for that point on the visual
field. A total of 15–20 positions were recorded from each side of
the SC, which provided a map of light sensitivity across the SC.
Data was expressed in table form as mean percentage of SC area
possessing a luminance threshold below a particular level.
Histology
At the end of testing at P100 or P150, rats were euthanized with
sodium pentobarbital (Sigma) overdose and perfused with
phosphate buffered saline (PBS). The superior pole of each eye
was marked with a suture to maintain orientation. The eyes were
then removed, immersed in 2% paraformaldehyde for one hour,
infiltrated with sucrose, embedded in OCT and cut into 10 mm
horizontal sections on a cryostat. Four sections (50 mm apart) were
collected per slide as 5 series. One series was stained with cresyl
violet (CV) for assessing the injection site and retinal lamination.
The remaining slides were used for antibody staining, following
previous protocols [49]. The antibodies used in this study are listed
in Table 1. Retinal sections were examined by regular and confocal
microscopy. Some blocks were embedded in plastic and semi-thin
sections were collected for examination at higher resolution.
Data Analysis
Statistical analyses were performed using GraphPad Prism version
3.02 for Windows (GraphPad Software, San Diego California
USA). Data are presented as mean6standard error of the mean
(SEM). Statistical analyses were made using either Student’s two-
tailed unpaired t test or analysis of variance (ANOVA) as specified
in the figure legends, and Newman-Keuls procedure was used for
multiple comparison analysis. Differences were considered to be
significant at p,0.05.
RESULTS
Human neural progenitors have an innate capacity
to secrete specific growth factors and can be
genetically modified to release GDNF
Prior to transplantation, we analyzed the in vitro production of
specific growth factors by unmodified hNPC
ctx and by hNPC
ctx
transduced with a lentiviral gene construct designed to constitutively
express GDNF (hNPC
ctx-GDNF) [11,44]. This provided an ap r i o r i
indication of their potential to influence host cells in a paracrine
manner, a mechanism postulated to underlie protective effects
observed in previous cell transplant studies [29,39,42,43].
ELISA was used to quantify the release of three molecules with
potential neuroprotective activity in the brain or retina: IGF-1
[50–52], FGF-2 [26,53,54] and GDNF [11,22–30]. Human
NPC
ctx or NPC
ctx-GDNF were grown as neurospheres for
approximately 39 population doublings (Figure 1A), at which
time they were dissociated and analyzed for growth factor release.
IGF-1 and FGF-2 were secreted into hNPC
ctx conditioned
medium at a rate of 280690 and 12.063.0 picograms/10
6
cells/day, respectively (Figure 1B). Unmodified hNPC
ctx did not
secrete GDNF at levels above background. In contrast, transgenic
hNPC
ctx-GDNF cultures released GDNF at a rate of 102.5629.9
nanograms/10
6 cells/day (Figure 1B). Immunocytochemical
analysis revealed that 75.9611.8% of the hNPC
ctx–GDNF
Vision and Neural Progenitors
PLoS ONE | www.plosone.org 3 March 2007 | Issue 3 | e338population stably expressed the lentiviral gene construct. Thus,
hNPC
ctx have the capacity to secrete endogenous growth factors of
known importance for the maintenance and survival of retinal
neurons, as well as the ability to constitutively express transgenes
encoding selected neurotrophins.
Subretinal injection of human neural progenitors
preserves retinal and visual functions
RCS rats received unilateral subretinal injections of hNPC
ctx,
hNPC
ctx-GDNF or medium alone (sham) at P21. Fellow,
untreated eyes served as internal controls for each animal. The
first test performed was ERG, which provides a gross measure of
retinal function and an indication of relative rod and cone efficacy.
In the scotopic-adapted RCS rat, the ERG a-wave (indicative
mainly of rod activity) disappears by P60, while the composite b-
wave (comprising rod and cone activity) is largely lost around P100
[39]. At approximately P100, eyes receiving either hNPC
ctx
(n=21) or hNPC
ctx-GDNF (n=9) injections retained robust ERG
responses (Figure 2). In contrast, sham-treated eyes (n=3) had no
measurable ERG responses at this age. Further comparison of eyes
injected with hNPC
ctx-GDNF or hNPC
ctx revealed significantly
greater a-wave and cone b-wave amplitudes in the GDNF-secreting
group (a-wave: 164.3663.7 mvv s .3 5 . 2 66.2 mv( p,0.05); cone b-
wave: 195.4638.1 mvv s .7 7 . 7 610.6 mv( p,0.01), respectively). For
perspective, non-dystrophic rats yielded a-wave and cone b-wave
responses of 2796172 mv and 3576183 mv, respectively. Thus, eyes
grafted with hNPC
ctx-GDNF retained ERG activity at approxi-
mately 58.8% (a-wave) and 54.6% (cone b-wave) of the level of
normal, non-dystrophic animals. Composite b-wave and rod b-wave
amplitudes were also well-preserved in the cell-injected eyes, but no
significantdifferencewasobservedbetweenthehNPC
ctx-GDNFand
hNPC
ctx groups (composite b-wave: 244.9645.3 mvv s .1 5 6 . 4 6
18.7 mv( p=0.12); rod b-wave: 57.6634.5 mv vs. 78.7610.5 mv
(p=0.84), respectively).
We next asked whether spatial visual acuity was affected by the
transplants using the optomotor, or head tracking, test [47,55]. At
approximately P100, eyes receiving hNPC
ctx (n=21) injections
performed significantly better than sham-operated (n=4) or
untreated (n=29) control eyes (0.5060.01 c/d vs. 0.2260.03 c/
d( p,0.001) or 0.1460.02 c/d (p,0.001), respectively) (Figure 3).
Eyes injected with hNPC
ctx-GDNF (n=11) possessed an average
visual acuity similar to hNPC
ctx recipients (0.5160.02 c/d vs.
0.5060.01 c/d, p=0.90), with some animals in both groups
retaining acuities within the normal, non-dystrophic range (0.56–
0.62 c/d). Sham-operated eyes also retained significantly better
Table 1. Sources and Working Dilutions of Antibodies for Immunohistochemistry.
..................................................................................................................................................
Antigen Antiserum Working dilution Source
Human nestin Mouse anti-nestin 1:200 Chemicon International
Human nuclei Mouse anti-human nuclei 1:300 Chemicon International
Human PCNA Mouse anti-PCNA 1:3000 Sigma
Cone arrestin Rabbit anti-LUMIJ 1:500 Drs. Zhu and Craft, U. So. California
PKCa Rabbit anti-PKCa 1:1000 Sigma
Rhodopsin Mouse anti-rhodopsin 1:1000 Dr. Molday, U British Columbia
Calbindin Rabbit anti-calbindin 1:1000 Swant, Switzerland
Parvalbumin Rabbit anti-parvalbumin 1:3000 Swant, Switzerland
Bestrophin Mouse anti-bestrophin 1:100 Chemicon International
RPE65 Mouse anti-RPE65 1:300 Chemicon International
doi:10.1371/journal.pone.0000338.t001
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Figure 1. Unmodified and transgenic human neural progenitor cells
secrete neuroprotective factors in vitro. (A) Light microscopic appearance
of neurospheres cultured from human prenatal cortical progenitor cells
(hNPC
ctx). Transgenic neurospheres formed following infection of
dissociated hNPC
ctx with a lentiviral vector encoding GDNF had an
identical appearance in culture. (B) ELISA results quantifying the release
of GDNF, IGF-1 and FGF-2 into conditioned media from hNPC
ctx and
hNPC
ctx–GDNF cultures. IGF-1 and FGF-2 were secreted by hNPC
ctx,
while GDNF was only detectable in transgenic hNPC
ctx-GDNF cultures.
Data are expressed as mean6SEM from n=3–6 independent samples.
(ND: not detectable).
doi:10.1371/journal.pone.0000338.g001
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0.1460.02 c/d, p,0.05), as shown previously. However, cell-
grafted animals tested at P150 continued to perform as high as
0.49 c/d (data not shown), whereas no measurable response was
observed in any of the sham-operated or untreated retinas at this
late time point. Of note, the sham responses obtained in these
experiments were essentially identical to those obtained in other
studies using the RCS rat [43].
Luminance threshold recordings from the SC measure
functional sensitivity across the visual field, which in turn provides
a geographic indication of the magnitude and area of photore-
ceptor rescue across the retina [56]. In dystrophic RCS rats,
threshold levels at P100 are greater than 3.0 log units above the
background level of 0.02 log candela/m
2. This is in comparison to
non-dystrophic rats, which possess threshold levels less than 0.6 log
units above background [48]. For the present study, recordings
were made in a combined set of cell-injected animals who received
either hNPC
ctx or hNPC
ctx-GDNF. Eyes were specifically chosen
from either group based on their superior performance on optomotor
testing; therefore, comparisons between the hNPC
ctx and hNPC
ctx-
GDNF groups arenot appropriate. Overall, cell-injected eyes (n=10)
performed significantly better than untreated eyes (n=5) or those
receiving sham injections (n=3) (Figure 4 and Table 2). Specifically,
8.065.8% of the SC area of cell-injected eyes produced thresholds
less than 0.8 log units, 22.068.5% produced thresholds less than 1.5
log units and 67.7610.0% yielded thresholds less than 2.1 log units,
with best test points falling within the normal, non-dystrophic range.
These results are in contrast to sham-injected eyes, where only
14.868.3% of the SC area yielded thresholds below 2.1 log units.
In summary, eyes receiving human neural progenitor cells
retained dramatically better retinal and visual functions compared
to control eyes at P100. Furthermore, some components of the
ERG were augmented when hNPC
ctx were engineered to release
GDNF.
Figure 2. The capacity of human neural progenitors to preserve retinal
function is augmented by GDNF expression. ERG response amplitudes to
full field light stimulation were recorded at approximately P100 in RCS
rats injected with hNPC
ctx–GDNF (n=9), hNPC
ctx (n=21) or medium
alone (n=3) into the subretinal space. Individual components of the
ERG waveform (a-wave, composite b-wave, cone b-wave and rod b-
wave) reveal relative contributions of different retinal cells to the overall
functional activity of the retina. Cone b-waves were delineated by
a double flash protocol and the rod-attributable b-wave was derived by
subtraction from the composite level. Eyes injected with hNPC
ctx–GDNF
demonstrated significantly greater a-wave and cone b-wave amplitudes
than those receiving hNPC
ctx (*p,0.05; **p,0.01; Student’s unpaired t-
test). In contrast, the composite b-wave and rod b-wave amplitudes
were not statistically different between the two groups. Control eyes
injected with medium alone (sham-operated eyes) had no recordable
ERG waves and are not included in the graph. Data are expressed as
mean 6 SEM.
doi:10.1371/journal.pone.0000338.g002
Figure 3. Spatial visual acuity is preserved in eyes receiving human neural
progenitor cell grafts. Rapid, non-invasive measurements of spatial visual
acuity thresholds were obtained using the OptoMotry head tracking
apparatus. At approximately P100, eyes receiving subretinal hNPC
ctx-
GDNF (n=11) or hNPC
ctx (n=21) demonstrated superior spatial visual
acuity compared to sham-injected eyes (n=4; ***p,0.001), with best-
grafted animals yielding near-normal responses (0.6 c/d). Spatial visual
acuity was also significantly better in sham-treated vs. untreated (n=29;
*p,0.05) eyes, reflecting the known ‘‘sham effect.’’ Statistical signifi-
cance was determined via one-way ANOVA with the Newman-Keuls
procedure for multiple comparison analysis.
doi:10.1371/journal.pone.0000338.g003
Figure 4. Visual field is preserved in eyes receiving human neural
progenitor cell grafts. Luminance threshold responses were recorded at
approximately P100 from multiple points within the superior colliculus
(SC) contralateral to the eye being tested. This method quantifies
functional sensitivity to light across the visual field of an eye. The
topographical map depicts the luminance threshold responses
(measured in log units relative to background illumination of 0.02 cd/
m
2) at 15 points within the SC opposite the cell-injected eye of a best-
performing animal at P104 (right side of figure). SC recordings (16
points) opposite the fellow, untreated eye (left side of figure) served as
an internal control. Both hNPC
ctx–GDNF and hNPC
ctx transplant
recipients were included in the cell-injected group, which consisted
of a select population of eyes that displayed superior performance on
spatial visual acuity testing. Recordings falling at or below a threshold
of 2.0 log units are indicated with unfilled ovals, while recordings above
2.0 are demarcated with filled ovals.
doi:10.1371/journal.pone.0000338.g004
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integrate, and form a new pigmented subretinal cell
layer that protects photoreceptors from
degeneration
An antibody recognizing human-specific nuclear antigen was used
to identify surviving hNPC
ctx and hNPC
ctx-GDNF at P100 and
P150. Both unmodified and genetically modified groups were
found to have cells that migrated and survived in two distinct
locations: (i) as a separate, nearly continuous, subretinal layer lying
between the host RPE and photoreceptors, and (ii) as individual
cells distributed throughout the neurosensory retina, especially
within the inner retinal layers (Figure 5A).
Donor cells comprising the semi-continuous subretinal layer
possessed intracellular pigment granules (confirmed on semi-thin
sections) similar to host RPE cells, unlike those that migrated
within the neurosensory retina, which remained unpigmented
(Figure 5B). The pigmented subretinal donor cells failed to express
two characteristic RPE markers, RPE65 [57] and bestrophin [58],
arguing against the possibility that they had undergone full
transdifferentiation. However, the photoreceptor outer segment
debris zone normally found in the subretinal space of the RCS rat
was nearly absent. A small number of donor cells in both the
intraretinal and subretinal locations were immunopositive for
proliferating cell nuclear antigen (PCNA) (Figure 5C and D), even
in the oldest rats examined (P150). Despite this potential indication
of continued cell division, there was no evidence of uncontrolled
growth or tumor formation at any time, suggesting that donor cell
proliferation might be regulated or balanced by cell death.
Qualitative examination of the host anatomical response to the
presence of hNPC
ctx or hNPC
ctx-GDNF revealed substantial
preservation of the photoreceptor outer nuclear layer (ONL)
overlying all subretinal donor cells (Figure 5E and F), with
photoreceptor rescue gradually declining outside the distribution
of the transplanted cells (Figure 5E and G). Distant from the
subretinal grafts, the ONL was reduced to a single layer at P100
and discontinuous, scattered cells at P150 (Figure 5G), similar to
untreated and sham-treated dystrophic retinas. Of interest, no
ONL was seen in areas where donor cells were present exclusively
in the inner retina, whereas a prominent ONL was present in
areas where donor cells existed solely in the subretinal space. This
observation suggests that subretinal localization of hNPC
ctx is
necessary and sufficient to promote anatomic rescue of the ONL
in this model.
Donor cells (hNPC
ctx or hNPC
ctx-GDNF) that migrated within
the neurosensory retina did not express the retinal markers
recoverin (Figure 6A), PKCa (Figure 6B), rhodopsin, parvalbumin
or calbindin (latter markers not shown). However, the morphology
of the host inner retinal cells was well-preserved in the area of
donor cell migration, as evident from the PKCa antibody staining,
which labeled normal-appearing rod bipolar cell dendrites
(upward arrows in Figure 6B). Both the intraretinal and subretinal
donor cell populations were immunopositive for nestin, a neural
stem and progenitor cell marker, using a human-specific antibody.
In addition, confocal microscopy showed a small portion of the
transplanted hNPC
ctx remained GFAP-positive (not shown).
Confocal microscopy further demonstrated an extensive network
of nestin-positive cellular processes emanating from the trans-
planted cells present within the neurosensory retina (Figure 6C),
which was not observed in the subretinal hNPC
ctx population.
While preservation of the ONL is evidence for a neuroprotective
role for hNPC
ctx and GDNF within the retina, maintenance of
visual function at the level observed in this study suggests at least
partial retention of photoreceptor structure necessary for visual
processing, particularly that associated with cones. To examine
host cone photoreceptors, we performed antibody staining for
cone arrestin antigen. In the area of best rescue, clearly identifiable
cones were present at a density of 40–46 cells/mm across two-
thirds of the histological section, even at 150 days of age (130 days
after transplantation). This cone density is within the range seen in
normal rat retinae, although cone processes in the rescued regions
were clearly shorter than normal and poorly organized (Figure 6D
and E). In contrast, cone photoreceptors were essentially absent in
sham-operated or untreated eyes at the same time point
(Figure 6F). This finding correlates with the partial preservation
of cone ERG activity, visual acuity and visual field observed in
cell-transplanted eyes.
DISCUSSION
Results from this study show that neural progenitor cells derived
from developing human cortex promote long-term preservation of
vision after subretinal transplantation in the RCS rat. Using three
independent tests performed at P90-100, hNPC
ctx- and hNPC
ctx-
GDNF-transplanted eyes demonstrated retention of visual func-
tions at levels among the best documented in the RCS rat model
[29,38,40–43,56,59,60]. These results correlated with survival of
photoreceptors, including cone cells, which are required for
optimal daylight vision. In contrast, sham injections of medium
alone failed to achieve significant sustained functional rescue,
consistent with previous studies. It has also been shown that
fibroblasts [43,60] and placenta-derived progenitor cells [43] are
unable to maintain visual functions long-term, further indicating
that the rescue effects seen in the RCS rat model are not the result
of a non-specific event. Of note, while vision rescue requires
preservation of some functional photoreceptors, the mere presence
of photoreceptor cells in the ONL of transplanted RCS rats does
not assure function [61]. Thus, we chose to emphasize quantitative
functional responses to hNPC
ctx transplantation and support these
findings with a more qualitative investigation of the host
anatomical impact.
Histological examination reveals that hNPC
ctx survive, migrate
and assume two substantially different appearances and distribu-
tions following transplantation into the subretinal space of RCS
rats. These findings were seen regardless of whether the cells were
Table 2. Summary of Visual Threshold Measurements from the Superior Colliculus in Different Groups of Animals.
..................................................................................................................................................
Group n Mean area 6 SEM of superior colliculus (in %) with log thresholds at level less than:
0.2 0.8 1.5 2.1 2.8 3.4 4.1 4.7
Cell-injected 10 0 8.065.8 22.068.5 67.7610 83.869.6 96.763.3 98.361.7 99.260.8
Sham 3 0 0 0 14.868.3 66.366.4 97.662.4 100 100
Untreated 5 0 0 0 0 0 40.9613.8 92.962.4 98.360.9
doi:10.1371/journal.pone.0000338.t002
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Vision and Neural Progenitors
PLoS ONE | www.plosone.org 6 March 2007 | Issue 3 | e338Figure 5. Human neural progenitors survive as two distinct populations within the retina and promote photoreceptor rescue. (A) Retinal section obtained
from a P150 eye immunostained with human-specific nuclear marker. There is a pigmented RPE-like (RPE-L) layer of donor cells above the host RPE
layer, whereas donor cells in the inner retina do not have pigment granules (right-pointing arrows). (B) High power image showing pigment granule-
containing donor cells in the RPE-L region that are positive for human nuclear marker (arrows). Photoreceptor inner segments (IS) are visible above
the pigmented donor cell layer, demonstrating partial preservation of photoreceptor structure. (C) Retinal section from the same eye used in panel A
stained with proliferating cell nuclear antigen (PCNA) revealing occasional dividing cells in the RPE-L layer and inner retina at P150 (arrows). (D) High
power image showing PCNA-positive cells in the RPE-L layer (arrows). (E) Low power view of a retina section obtained from the same eye used in
panel A showing extensive rescue of photoreceptors within the outer nuclear layer (ONL) after subretinal injection of hNPC
ctx–GDNF. The boxes
labeled f and g correspond to the high power images depicted in panels F and G, respectively. (F) High power view of box f from panel E showing
rescued ONL and the underlying, semi-continuous layer of donor cells between the photoreceptors and RPE (arrow). (G) High power view of box g
from panel E showing non-rescued ONL distant from surviving subretinal donor cells. INL: inner nuclear layer; IS: inner segments; ONL: outer nuclear
layer; RGC: retinal ganglion cell layer; RPE-L: RPE-like layer.
doi:10.1371/journal.pone.0000338.g005
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PLoS ONE | www.plosone.org 7 March 2007 | Issue 3 | e338Figure 6. Transplanted human neural progenitors express nestin in vivo and partially preserve host cone structure. Confocal images of P150 dystrophic
retina transplanted with hNPC
ctx–GDNF and double stained with antibodies against human nuclear antigen (red) and either (A) recoverin,
a photoreceptor and cone bipolar cell marker (green), or (B) protein kinase Ca (PKCa), a bipolar cell marker (green). Down arrows point to subretinal
donor cell nuclei in panel B, while up arrows point to preserved dendrites of host rod bipolar cells. Note the location of donor cell nuclei in both the
inner retina and subretinal space. (C) Confocal image of P150 dystrophic inner retina transplanted with hNPC
ctx–GDNF and double stained with
antibodies against nestin, a neural stem and progenitor cell marker (green) and human nuclear antigen (red). (D) Confocal image of non-dystrophic,
control retina stained with cone arrestin antibody (red) showing a normal cone photoreceptor profile (IS: inner segments; ax: axon; arrows point to
cone pedicles). (E) P150 dystrophic retina transplanted with hNPC
ctx–GDNF and stained with cone arrestin antibody showing morphology of rescued
cone photoreceptors (arrows point to cone pedicles). (F) Sham-operated retina at P150 stained with cone arrestin antibody (arrows point to rare
remaining cone cell bodies). Results at P150 from retina transplanted with hNPC
ctx were similar to those receiving hNPC
ctx–GDNF. IPL: inner plexiform
layer; ONL: outer nuclear layer; RGC: retinal ganglion cell layer; RPE-L: RPE-like layer.
doi:10.1371/journal.pone.0000338.g006
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PLoS ONE | www.plosone.org 8 March 2007 | Issue 3 | e338previously transduced with a GDNF-expressing construct. One
population is non-pigmented and diffusely distributed within the
inner retina, while the other is a pigment granule-containing,
RPE-like layer located between the host neurosensory retina and
RPE. In previous studies using other donor cell types, significant
intraretinal migration was not seen [39,41], nor were pigment
granules found in donor cells not originally derived from RPE
[39]. However, similar to other reports introducing forebrain–
derived stem cells into the retina [13–17], donor cells used in this
study did not express markers typical of host retinal cells. Our
observations imply that donor cell location within host tissue can
influence their apparent phenotype, even though they lack critical
markers of the cells they come to resemble.
The mechanism by which human neural progenitor cells exert
their effects within the retina is not wholly clear, but is likely due in
part to growth factor production [39] and possibly also to the
manifestation of some RPE-like properties. With respect to factor
production, we have detailed at least two factors, IGF-1 and FGF-
2, that hNPC
ctx produce in vitro that could be effective in
promoting vision and photoreceptor preservation. A more
comprehensive survey may identify others. Thus, transplanted
hNPC
ctx have the potential to release multiple growth factors,
which may act synergistically to slow photoreceptor degeneration
[62,63]. The superior performance of hNPC
ctx-GDNF is consis-
tent with both the known role of GDNF as a neuroprotective
molecule within the retina [25–30] and the established ability of
hNPC
ctx to function as a cell-based drug delivery vector in diverse
CNS tissues [11,12]. The additional capacity of hNPC
ctx to
migrate extensively within the subretinal space and inner retina
allows them to deliver molecules of therapeutic interest not only
for outer retinal disease (e.g., retinitis pigmentosa and age-related
macular degeneration), but inner retinal disorders as well (e.g.,
glaucoma). Panretinal donor cell migration also affords better
access to Mu ¨ller glia, which bind and mediate host responses to
some neurotrophic factors, including GDNF [26].
The additional question of whether hNPC
ctx might mimic some
of the functions of RPE is an intriguing one. A population of these
cells forms a layer deep to the photoreceptors, where they contain
intracellular pigment granules and appear superficially like an
extra RPE layer, even though they do not express at least two
characteristic RPE proteins. The presence of intracellular pigment
granules along with the absence of a subretinal cellular debris zone
raise the possibility that these donor cells have (or acquire) the
capacity to phagocytose surrounding waste material. As this is one
function of healthy RPE [64], such activity may contribute to the
cell transplant-mediated rescue observed, a possibility that is being
explored further.
The fact that donor cells continue to divide until P150 is
a matter of both concern and optimism. Previous work has shown
that ES-derived RPE cells can develop teratomas [65], although
not in all cases [42]. However, in the present study there is no
evidence of untoward donor cell proliferation or tumor formation
up to at least 130 days post-transplantation, suggesting that cell
division is a regulated or balanced event. Indeed, persistent cell
division may contribute to the sustained high performance of
hNPC
ctx transplant recipients over time. Even so, later time points
are needed to ensure that tumors never form within the retina after
transplantation of hNPC
ctx.
In summary, transplanted hNPC
ctx display a novel profile of
properties that produce profound rescue of visual functions in the
RCS rat, an animal model of photoreceptor loss secondary to RPE
dysfunction. The potential for native or modified hNPC
ctx to
deliver neurotrophins and rescue cones and photopic vision in
primary rod degeneration models also needs to be assessed.
However, current results point to a possible role for hNPC
ctx in the
treatment of at least some forms of human retinal degenerative
diseases and highlight the versatility and efficacy of these cells as
therapeutic tools in a broad range of neurodegenerative disorders
[10–12,66]. A current clinical trial investigating the use of
transplanted human neural stem cells in Batten disease [67] will
address questions concerning the safety of this cell type and
provide important background for contemplating their clinical
application in retinal disease.
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